Go back

Alzheimer’s drug insider trading case heats up

An insider trading case is coming to a head involving a former portfolio manager at CR Intrinsic, a unit of SAC Capital, who allegedly worked with a University of Michigan Medical School neurology professor to gain information about a clinical trial of an Alzheimer’s disease drug.

The defendant, Mathew Martoma, is accused of using that inside information to earn more than a quarter of a billion dollars on shares of Elan Corp. and Wyeth LLC.

This article on Research Professional News is only available to Research Professional or Pivot-RP users.

Research Professional users can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.